Hussein Tawbi, MD, PhD: Hello. My name is Hussein Tawbi. I’m a melanoma medical oncologist at MD Anderson Cancer Center. I’m professor and deputy chair of the Department of Melanoma Medical Oncology and co-director of the Brain Metastasis Clinic here at MD Anderson Cancer Center. What we’re discussing today is a case of an unfortunate lady in her 40s, specifically a 47-year-old lady who presented with a 2.2-millimeter primary melanoma of the skin of her left thigh.
Publications
FDA Grants Orphan Drug Designation to LNS8801 for Metastatic Cutaneous Melanoma
The FDA has granted orphan drug designation for LNS8801 for the treatment of patients with metastatic cutaneous melanoma, according to Linnaeus Therapeutics, Inc.
Immune Checkpoint Inhibitors and CVD Risk in Patients With Melanoma
Immune checkpoint inhibitor (ICI) therapy may increase the risk of major atherosclerotic cardiovascular events (MACE) in patients with high-risk or advanced melanoma, according to a study published in Cardio-Oncology.
Iovance to Address FDA Requests for BLA of Lifileucel in Advanced Melanoma
After receiving recent FDA feedback regarding supplemental assay validation information and comparability data for lifileucel (LN-44) in the treatment of advanced melanoma, Iovance Biotherapeutics will address these comments and plans to complete its rolling biologics license application (BLA) submission during the first quarter of 2023.